Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628542 | 0.85 | HTR1A (0.72) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6847481 | 0.84 | HTR1A (0.78) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6626218 | 0.84 | HTR1A (0.70) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6335373 | 0.84 | HTR1A (0.65) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6628788 | 0.84 | HTR1A (0.72) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6843634 | 0.84 | HTR1A (0.72) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6628786 | 0.83 | HTR1A (0.69) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL5844673 | 0.83 | HTR1A (0.69) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6767324 | 0.83 | HTR1A (0.71) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6627811 | 0.82 | HTR1A (0.68) | HTR1ASLC6A4KDM4ELMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800648-B2 | SCHIZOPHRENIA, BIPOLAR DISORDERS, PARKINSON'S DISEASE; DRUG ABRUSE | WYETH | 2004-10-05 | — | — | US | claimed |
| US-20030073697-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-1,6,9-trioxa-3-AZA-cyclopenta[a]naphthalen-2-one | WYETH | 2003-04-17 | — | — | US | claimed |
| WO-2002088142-A1 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[a]NAPHTHALEN-2-ONE | WYETH (US) | 2002-11-07 | — | — | WO | claimed |
| US-6800648-B2 | SCHIZOPHRENIA, BIPOLAR DISORDERS, PARKINSON'S DISEASE; DRUG ABRUSE | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20030073697-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-1,6,9-trioxa-3-AZA-cyclopenta[a]naphthalen-2-one | WYETH | 2003-04-17 | — | — | US | disclosed |
| WO-2002088142-A1 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[a]NAPHTHALEN-2-ONE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073697-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-1,6,9-trioxa-3-AZA-cyclopenta[a]naphthalen-2-one | SNCA, TUBA1C, SLC6A3 | HTR1A 20/4885SLC6A4 236/4885KDM4E 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.